Also considered
16 papers judged, 0 emailed · Read the digest →
Systematic review and meta-analysis of phase 3 trials examining how patient sex and timing (neoadjuvant vs adjuvant) affect outcomes with curative-intent immune checkpoint inhibitors across solid tumors, published in JAMA Network Open. Findings could inform how oncologists interpret and sequence perioperative immunotherapy across tumor types by patient sex.
Retrospective biomarker study developing a NECTIN4 amplification and membranous expression scoring system to predict enfortumab vedotin response in metastatic urothelial carcinoma, published in Clinical Cancer Research. Validated against EV-301 trial data, this could help identify patients most likely to benefit from EV therapy.
Translational/biomarker study in Eur Urol Oncol using patient-derived models and clinical cohorts showing that gemcitabine-cisplatin exposure downregulates Nectin-4 and confers cross-resistance to enfortumab vedotin in bladder cancer. Suggests assessing Nectin-4 expression after platinum chemotherapy could inform sequencing decisions before EV use.
Secondary analysis of two phase 3 trials (CheckMate-214, CheckMate-9ER) developing and validating a new prognostic model for metastatic clear cell RCC in the checkpoint-inhibitor era, published in Lancet Oncology. Offers an updated risk-stratification tool but does not itself guide specific drug selection.
Meta-analysis of 25 studies evaluating ctDNA-detected AR gene alterations as a prognostic marker in mCRPC patients treated with enzalutamide/abiraterone, published in Clinical Genitourinary Cancer. Shows AR alterations predict worse survival, though the association weakens after prior AR-targeted therapy, informing prognostic risk stratification rather than a new treatment decision.
Retrospective international registry study of PSMA-PET imaging in nonmetastatic castration-resistant prostate cancer, published in European Urology Focus. Shows PSMA-PET-derived tumor volume prognosticates overall survival, informing risk stratification but not a specific therapeutic decision.
Narrative perspective/review in European Urology Oncology revisiting transdermal estradiol as an androgen deprivation therapy option for prostate cancer, highlighting potential advantages over standard ADT formulations. Offers a case for reconsidering estrogen-based hormonal therapy in advanced prostate cancer management.
Narrative review in Frontiers in Oncology proposing a framework for interpreting FDG/PSMA imaging discordance to identify target-insufficient disease in metastatic castration-resistant prostate cancer patients being considered for Lu-PSMA therapy. Could inform patient selection for radioligand therapy pending prospective validation.
Preclinical/translational study in Nature Cancer showing a gut commensal fungus translocates to prostate tumors under androgen deprivation therapy and drives immunosuppression and cancer progression in mouse models. Suggests a novel mechanism of endocrine resistance and a potential future therapeutic target, but lacks patient-level clinical outcome data.
Secondary analysis of two STAMPEDE phase 3 trials linking hospital-record data, published in European Urology, examining fracture-related hospitalization risk with abiraterone-based treatment intensification in high-risk/metastatic prostate cancer. Findings suggest abiraterone intensification did not increase (and may lower) fracture hospitalization risk, informing bone-health counseling in this setting.
Retrospective cohort study in Clinical Genitourinary Cancer of men with metastatic hormone-sensitive prostate cancer, showing that early achievement of ultra-low PSA levels after first-line ADT-based therapy correlates with longer radiographic progression-free survival. Suggests early PSA kinetics could help gauge treatment response and prognosis in mHSPC.
Prospective multicenter cohort study in metastatic hormone-sensitive prostate cancer, published in JCO Precision Oncology. Baseline ctDNA tumor fraction is prognostic for survival and time to castration resistance, but the study is primarily prognostic rather than predictive of a specific therapy choice.
Post hoc analysis of the phase 3 TITAN trial in metastatic castration-sensitive prostate cancer, published in European Urology Focus. Characterizes how apalutamide alters patterns of progression to castration resistance and their prognostic significance, offering nuance for monitoring but not changing first-line treatment choice.
Retrospective cohort study (n=35) evaluating feasibility of immune-related pathologic response criteria after neoadjuvant systemic therapy in renal cell carcinoma, published in Eur Urol Oncol (Q1). Suggests pathologic response assessment may better reflect outcomes than radiographic response, but the criteria don't yet inform a specific treatment decision.
Retrospective single/multi-center study of Lu-177-PSMA-617 retreatment in metastatic castration-resistant prostate cancer, published in Frontiers in Oncology. Offers real-world data supporting retreatment as a feasible option for patients who previously responded to radioligand therapy.
Preclinical study in J Immunother Cancer describing a synthetic 'NOT gate' CAR-T design to reduce neurotoxicity from PSMA-targeted prostate cancer therapy, tested in vitro and in mouse models. Offers a potential engineering strategy to improve safety of PSMA-directed cellular therapies, but no clinical/patient data yet.